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ABSTRACT Host infection by microbial pathogens cues global changes in microbial and host cell biology that facilitate microbial
replication and disease. The complete maps of thousands of bacterial and viral genomes have recently been defined; however, the
rate at which physiological or biochemical functions have been assigned to genes has greatly lagged. The National Institute of
Allergy and Infectious Diseases (NIAID) addressed this gap by creating functional genomics centers dedicated to developing
high-throughput approaches to assign gene function. These centers require broad-based and collaborative research programs to
generate and integrate diverse data to achieve a comprehensive understanding of microbial pathogenesis. High-throughput
functional genomics can lead to new therapeutics and better understanding of the next generation of emerging pathogens by
rapidly defining new general mechanisms by which organisms cause disease and replicate in host tissues and by facilitating the
rate at which functional data reach the scientific community.
Microbial genome sequencing efforts continue at an increas-ing rate, resulting in an expanding catalogue of genes of
unknown function for important pathogens (Fig. 1). In some
cases, up to 40% of the annotated genes in fully sequencedmicro-
bial genomes have no known or predicted function. In many
cases, these uncharacterized genes are highly conserved and are
implicated in the pathogenic process through either their timing
of expression or requirement for microbial replication. Such data
indicate that these genes execute important, general biological
functions. The interpretation of existing and emerging microbial
genomics data will require the scientific community to uncover
new paradigms hidden within these sequences. This point is high-
lighted by a recent publication by Hutchison et al. focused on
building a minimal genome ofMycoplasma mycoides (1). The 473
genes in this genome include many required for known essential
functions, such as DNA replication, transcription, and transla-
tion, but the genome also contains 149 genes (~31%) of unknown
function. Likewise, the known coding capacity of DNA viruses has
been doubled over the past few years, an achievement made pos-
sible by using novel high-throughput sequencing and proteomic
methods. The discovery of these genes of unknown function not
only promises to affect our understanding of microbial pathogen-
esis but also provides an undiscovered wealth of new therapeutic
targets for antibiotic, antiviral, and vaccine development for im-
proved global and economic health.
Unlike large-scale genome-sequencing or structural-genomics
efforts, the functional annotation of uncharacterized genes is not
well developed technologically, and therefore, the scientific com-
munity cannot rely on a well-defined, mature set of experimental
approaches. Simple deletion or overexpression of an uncharacter-
ized gene often fails to yield any discernible phenotype in standard
laboratory contexts. In the same vein, a purely biochemical ap-
proach that relies on purification and in vitro biochemical charac-
terization of uncharacterized genes often fails to yield fruitful
functional data. Furthermore, while sequence-based bioinfor-
matic analyses and computational models may provide clues
about functional genetic interactions, such predictions are often
limited by our current biological knowledge and databases. As a
consequence, functional annotation is incorrect in many cases
because unvalidated information is propagated across species. In
cases where gene function is experimentally assigned and vali-
dated, the information is often not broadly propagated ormay not
apply to another organism. Therefore, a successful functional an-
notation endeavor requires a multipronged approach that in-
volves open collaboration among scientists with expertise in ge-
netics, bioinformatics, molecular biology, biochemistry, cell
physiology, host-microbe interactions, and data management.
Such a program is outside the scope of traditional funding mech-
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FIG 1 The current release of the protein sequence family database, Pfam
(version 30, July 2016; http://pfam.xfam.org/), contains 16,306 sequence fam-
ily entries, 3,751 of which are families/domains of unknown function (DUFs).
The release years for Pfam version 4.0 and version 30.0 are marked with ar-
rows.
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anisms and requires integrated teams of experts and new high-
throughput experimental methodologies.
The NIAID has implemented a program aimed at assigning
functions to open reading frames (ORFs) and small noncoding
RNAs (ncRNAs) that have been discovered by large-scale se-
quencing efforts to begin addressing this gap in our understanding
of bacterial and viral gene function. This timely initiative from the
NIAID is highly significant because it is the institute’s first attempt
to incorporate functional annotation into its genomics and ad-
vanced technologies program, which is focused on developing
genomics, proteomics, and bioinformatics resources to advance
our understanding of infectious and immune-mediated diseases.
The NIAID Functional Genomics (FG) program builds on previ-
ous functional annotation efforts, such as COMBREX (2), and
brings together multidisciplinary groups to work on shared goals.
Its mission is to probe new biology in pathogenic bacteria and
viruses by assigning functions to new genes. The FG program is
unique in its approach in that it enables principal investigators to
followup on “omics” and phenotypic screening datawith targeted
experiments to establish gene function.Most pathogens are evolv-
ing constantly, and such an integrated approach will provide the
database to allow us to work toward predicting new emerging
infectious diseases and respond to new pandemics.
Projects across the NIAID FG program are driven by the idea
that the assignment of gene function must be rooted in experi-
mentation in vivo and in vitro. The challenge to the experimental-
ist is to develop systematic approaches to gene function discovery
that have a reasonable chance of success over a large number of
genes. FG Centers are taking a variety of approaches to uncover
the functions of protein-coding genes and small ncRNAs. Some
approaches, which perhaps will have the highest yield, require at
least some prediction of function, while others presuppose no
specific functional knowledge. Current state-of-the-art technolo-
gies, such as genome synthesis, next-generation nucleic acid se-
quencing, ribosomal profiling, high-resolution mass spectrome-
try, metabolomics, and molecular and systems modeling, enable
high-throughput approaches to characterize genes of unknown
function. Though these technologies are clearly valuable, they are
most effectively leveraged when combined with functional assays,
such as measurements of microbial permeability and antimicro-
bial susceptibility or assays of host response to infection, which
have been scaled up through recent developments in robotics,
whole-genome synthesis, and high-content cellular imaging. In
this commentary, we provide an overview of our coordinated ef-
forts that are aimed at filling the gaps in our understanding of
microbial gene function. These efforts are restricted to a few or-
ganisms and technologies but could be attempted on a much
larger scale. Such functional analyses could provide the scientific
basis for rational approaches to the development of new therapeu-
tic products to combat future and current gaps in the treatment of
bacterial and viral infection.
IN VITRO AND BIOINFORMATIC APPROACHES
Improving the quality of genome maps. Most protein-coding
genes are annotated by either their similarity to known genes or
generalized guidelines for identifying translational start sites. Such
predictions are often incorrect. For example, we have demon-
strated that a protein highly homologous to a secreted bacterial
amidase is actually an intracellular regulator of peptidoglycan syn-
thesis (3). Moreover, predictive algorithms to define the locations
of non-protein-coding genes (e.g., small ncRNAs, out-of-frame
ORFs, etc.) are generally poor.Defining the boundaries of genes of
unknown function is an important component of experimental
functional annotation. We are using combinations of directed
biochemical, computational, and next-generation-sequencing
approaches to produce improvedmaps of gene boundaries in bac-
terial and viral pathogens. These efforts enable improved func-
tional genetic and biochemical experiments.
Leveraging existing protein structure data. Molecular struc-
ture data can provide tremendous insight into the biochemical
functions of proteins. A high-quality structuralmodel enables one
to map conserved residues on the molecule and to develop hy-
potheses regarding active-site chemistry, ligand binding sites, pro-
tein docking sites, etc. We are taking advantage of the large
amount of structural data available in the PDB to build homology-
based protein models. In addition, we are using hidden Markov
Model (HMM)-based approaches to build predictive structural
models in cases where homology in the PDB is low. Experimental
structures and high-confidence structural models generated by
the FG program are available to the community and have been
used to develop and test specific functional hypotheses in vitro and
in vivo and to define protein function (4).
High-throughput protein production for functional bio-
chemical analysis. Structural models of proteins of unknown
function are informing functional biochemical hypotheses that
are being tested in vitro. Specifically, we are leveraging existing
high-throughput structural genomics infrastructure to produce
expression clones of proteins of unknown function. This ap-
proach is yielding milligram quantities of many targets of un-
known function, which are being assayed for a range of biochem-
ical activities and are being used to produce antibodies for cellular
studies. One specific use for these purified proteins is in activity-
basedmetabolomic profiling (5), an unbiased approach to finding
substrates and products for putative enzymes.
Defining gene function by biochemical association. A well-
established approach to define function is to test for physical as-
sociations of proteins and RNAswith other proteins or transcripts
of known function. We are employing such biochemical associa-
tion strategies. For protein-coding genes, we are measuring
protein-protein associations using quantitative proteomic meth-
ods. For example, using a proteomics approach, we reported that
Kaposi’s sarcoma-associated herpesvirus (KSHV) viral interferon
regulatory factor 1 (vIRF1) can bind the cellular interferon-
stimulated gene 15 (ISG15) E3 ligase, HERC5. Interaction of
vIRF1 with HERC5 inhibits the conjugation of ISG15 to cellular
proteins, thereby dampening the IFN response to the virus (6).
Using a functional genomics screen, coupled with synthetic ge-
nome design, we demonstrated that the S glycoprotein genes of
several severe acute respiratory syndrome coronavirus (SARS-
CoV)-like bat coronaviruses can bind human receptors for entry
and replicate efficiently in primary human airway epithelial cells
and that they are resistant to existing SARS vaccines and immu-
notherapeutics (7, 8). Our early results suggest that an efficient
way to discover function using this approach is to target protein
complexes of known function and define associated proteins of
unknown function. These efforts have required us to develop new
bioinformatics methods to understand the complex data pro-
duced by these experiments.
Prediction of ncRNA targets. ncRNAs represent a particular
challenge in bacterial and virus research, as they can vary tremen-
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dously among different bacterial species and viruses and little is
known about their functions.We have generated catalogues of the
ncRNAs for the organisms (for example, inmycobacteria) (9) that
we study and are applying large-scale methods to identify their
targets. These methods start with bioinformatics, though the pre-
dictive algorithms are not yet particularly robust. In addition, we
are applying cross-linking-, ligation-, and sequencing-based ap-
proaches to systematically link small ncRNAs of unknown func-
tion to their transcript targets. Thus, while many of our ap-
proaches to investigating ncRNAs are still at the developmental
stage, defining catalogues of ncRNAs provides the community
with a road map of targets for downstream studies and analyses.
We are also using next-generation-sequencing technologies,
such as transcriptome sequencing (RNAseq) and selective 2=-
hydroxyl acylation analyzed by primer extension (SHAPE) analy-
sis of RNA, to investigate RNA structure-function correlations.
Pairedwith these analyses, we are investigating theRNA transcrip-
tome to correlate conserved and unique RNA structure elements
with pathogen virulence factors, identify previously uncharacter-
ized and/or rare translation initiation sites, and associate protein
structure elements with virus biology, pathogenesis, and host
range.
CELLULAR AND IN VIVO APPROACHES
Genetic approaches: identifying phenotypes.We are using mul-
tiple strategies to identify phenotypes that are associated with the
deletion or overexpression of target genes of unknown function.
For bacterial pathogens, we have initially focused on genes that,
when disrupted, producemeasurable growth phenotypes or alter-
ations in cellular barrier function under specified conditions, in-
cluding antibiotic treatment. These assays are facilitated bywhole-
genome-mutant definedmutant libraries that allowmore efficient
high-throughput screening for specific phenotypes (10).
We are assaying the growth of mutant strains in axenic culture
and in cell and animal infection models. The Biolog screening
platform provides a high-throughput approach to phenotype
identification. We are growing individual deletion strains in par-
allel with wild-type control strains under ~2,000 defined condi-
tions. Differences between strains identify specific medium con-
ditions under which a particular gene is required for wild-type
growth and have provided clues for target gene function (11). In a
particular case, a functional genetic study of mutants harboring
deletions of genes of unknown function is informing the develop-
ment of a new live attenuated Brucella abortus vaccine strain (12).
In addition, we are applying genome-wide screening approaches
to find genes that interact genetically to modify phenotypes.
In our studies of viral pathogens, we have developed a high-
throughput, multiarmed screening program to investigate both
RNA and DNA virus-encoded host evasion functions. To accom-
plish this, we are applying modular cloning technology to easily
shuttle candidate genes of unknown function into replicon ex-
pression and/or lentiviral vectors for alternate applications, such
as the expression of toxic or otherwise challenging proteins and
antibody generation. Using these screening assays, we are defining
viral counterdefense mechanisms mediated by known, novel, and
noncanonical viral ORFs and ncRNAs, whose products modulate
the host innate immune response and cellular defense machinery
to the virus’s advantage. Screening assays include assessments of
beta interferon (IFN-) antagonism, NF-B, Toll-like receptor,
and apoptosis modulation, inflammasome signaling, cGAS-
STING and p53 pathway modulation, cellular localization, global
protein synthesis, and mTOR inactivation. For example, we have
reported multiple herpesviral proteins that modulate the cGAS-
STING DNA sensing pathway and Middle East respiratory syn-
drome coronavirus (MERS-CoV) and closely related bat MERS-
like virus phosphodiesterase proteins that antagonize RNase L
activation during infection (13–15). In parallel, we also seek to
identify viral entry proteins that program efficient infections
across multiple species (7, 8). Our synthetic approach allows us to
rapidly test hypothetical proteins—proteins whose expression has
not yet been verified in the context of infection. Genes of interest
are then deleted or mutated using reverse genetic platforms, and
virus mutant growth is examined both in primary human targets,
such as airway epithelial cells and various immune cells, and dur-
ing infection.
SYNERGIES AND DATA SHARING
Synergies across the four centers funded by the FG program.
Although the four centers funded by the FG program have differ-
ent specific goals, we share approaches and are experiencing com-
mon challenges, which we are working to solve together. Shared
solutions drive research forward. For example, each center in-
cludes a small RNA (sRNA) discovery project. There is no gener-
ally agreed upon approach to elucidating sRNA gene function. It
has been useful to compare experiences and potential solutions
across centers. sRNA discovery projects as a group are converging
on approaches that may work generally in bacteria. In addition,
the data management groups at the four centers share common
priorities for public dissemination of data andwere able as a group
to begin the process of defining new priorities for updating capa-
bilities for the PATRIC and VIPR BRC public resources. An ex-
ample of this collaboration is the specification of the mode and
format for transfer of transposon-sequencing (Tn-Seq) experi-
mental data and Biolog phenotyping data to PATRIC, along with
the computational tools to analyze these data (16). This effort will
standardize the process of data transfer from independent centers
and will define the format for public display of these and other
data sets generated by FG Centers.
Another interaction is occurring with the Seattle Structural
Genomics Center for InfectiousDiseases and theCenter for Struc-
tural Genomics of Infectious Diseases. Using validated overex-
pression platforms and novel uncharacterized and/or hypotheti-
calORFs, the collaboration is designed to determine the structures
of high-priority candidate proteins that antagonize host antimi-
crobial defense pathways in the host. It is likely in the future that
the data we generate will be used by the systems biology centers to
further create more complex models of host-pathogen interac-
tions.
CONCLUSIONS
As described above, we have used a multipronged investigation
strategy to directly evaluate unknown and hypothetical genes
from a diverse array of pathogens to characterize the biological
functions encoded by these genes (Table 1). A particular strength
of this approach is that this systematic workflow, which can be
adapted to all pathogens with sequenced genomes, can ensure
rational, directed, and rapid response times for vaccine and ther-
apeutic design in answer to emerging and reemerging epidemics.
Thework of this program is defining a future blueprint to perform
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functional analysis of new pathogens as they emerge and to more
rapidly respond to the need for knowledge of emerging organisms.
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TABLE 1 Bacteria and viruses investigated in the NIAID functional
genomics program
Bacteria
Acinetobacter baumannii
Mycobacterium tuberculosis (and related mycobacteria)
Brucella abortus
Yersinia pestis
Viruses
SARS
MERS
Influenza
Ebola
KSHV
Zika
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